PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorsBreast CancerPancreatic CancerSolid TumorsOvarian CancerProstate CancerColorectal CancerNSCLC
- Interventions
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 73
- Registration Number
- NCT04672460
- Locations
- 🇺🇸
Mary Crowley Cancer Research - Medical City Hospital, Dallas, Texas, United States
🇺🇸West Chester Hospital, West Chester, Ohio, United States
🇺🇸California Cancer Associates for Research and Excellence, Inc (cCARE), San Marcos, California, United States
Study to Evaluate Safety and Tolerability of PF-07242813 in Healthy Participants and Participants With Atopic Dermatitis
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 121
- Registration Number
- NCT04668066
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸First OC Dermatology, Fountain Valley, California, United States
🇺🇸Keck School of Medicine of USC, Los Angeles, California, United States
Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1205
- Registration Number
- NCT04669366
- Locations
- 🇸🇪
Pfizer Innovations AB, Sollentuna, Sweden
Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
- Conditions
- Atopic DermatitisPlaque Psoriasis
- Interventions
- Drug: PF-07038124 ointmentDrug: Vehicle ointment
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 104
- Registration Number
- NCT04664153
- Locations
- 🇺🇸
Center for Clinical Studies, Houston, Texas, United States
🇵🇱Mazowieckie Centrum Badań Klinicznych, Grodzisk Mazowiecki, Poland
🇵🇱Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna, Lodz, Poland
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 256
- Registration Number
- NCT04657991
- Locations
- 🇩🇪
HELIOS Klinikum Erfurt, Erfurt, Germany
🇺🇸UCLA - Hematology/Oncology - Administrative Office, Los Angeles, California, United States
🇺🇸Ronald Reagan UCLA Medical Center Drug Information Center , Dept. of Pharmaceutical Services (Drug, Los Angeles, California, United States
Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2021-03-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT04655040
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Swedish Ibrance Registries Insights (SIRI)
- First Posted Date
- 2020-12-04
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1500
- Registration Number
- NCT04654208
- Locations
- 🇸🇪
Pfizer AB, Sollentuna, Sweden
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Conditions
- Pediatric Migraine
- Interventions
- Drug: Rimegepant/BHV3000Drug: Matching placebo
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2100
- Registration Number
- NCT04649242
- Locations
- 🇺🇸
Achieve Clinical Research, LLC d/b/a Accel Research Sites-Neurology and Neurodiagnostic of Alabama, Birmingham, Alabama, United States
🇺🇸Perseverance Research Center, LLC, Scottsdale, Arizona, United States
🇺🇸Physicians Research Group, Tempe, Arizona, United States
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 188
- Registration Number
- NCT04649359
- Locations
- 🇪🇸
Clinica Universitaria de Navarra, Madrid, Spain
🇯🇵Gunma University Hospital, Maebashi, Gunma, Japan
🇺🇸University of Iowa - Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
- Conditions
- Tick-Borne Encephalitis
- Interventions
- Biological: TBE vaccine 0.25 mLBiological: TBE vaccine 0.5 mL
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 165
- Registration Number
- NCT04648241
- Locations
- 🇯🇵
Ohigesenseino Kodomo Clinic, Sapporo, Hokkaido, Japan
🇯🇵Medical Co. LTA PS Clinic, Fukuoka,, Fukuoka, Japan
🇯🇵Watanabe Pediatric Allergy Clinic, Sapporo, Hokkaido, Japan